Ara
Toplam kayıt 611, listelenen: 311-320
Leflunomide as a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
(Wiley, 2018)
[No Abstract Available]
Association of Fetuin-A with Carotid Intima-Media Thickness and Vascular Diseases
(Springer, 2016)
Fetuin-A, also known as alpha 2-Heremans-Schmid glycoprotein (AHSG), is a member of the cystatin superfamily of cysteine protease inhibitors and has different functions in human physiology and pathophysiology. Most studies ...
Re: Heart rate recovery and methodological issues
(AVES Ibrahim Kara, 2015)
[No abstract available]
Supraorbital and infraorbital nerve blockade in migraine patients: results of 6-month clinical follow-up
(Verduci Publisher, 2013)
BACKGROUND: Nerve blockades are used for the treatment of acute migraine episodes in emergency room conditions and beneficial results are obtained from this clinical use. Although this is the case, there are limited numbers ...
The importance of examining antinuclear antibody (ANA) in neurological diseases
(2013)
Objective: In neurological clinical practice screening test for ANA (Anti-nuclear antibody) is helpful in the diagnosis of autoimmune diseases which have neurological involvement. ANA investigation tests might be positive ...
Bortezomib-induced peripheral neuropathy and neuronopathy in patients with multiple myeloma
(Springer Heidelberg, 2013)
[No Abstract Available]
The comparison of vep parameters in neuromyelitis optica spectrum disorders and multiple sclerosis patients with acute optic neuritis
(Istanbul Universitesi, 2020)
Introduction: Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are idiopathic, autoimmune, and central nervous system inflammatory diseases. The similarity in the clinical course of both diseases ...
Self-management and coping strategies in patients with multiple sclerosis - a multicenter-prospective study
(Sage Publications Ltd, 2019)
[No Abstract Available]
GX-G3, a long-acting G-CSF, compared with pegfilgrastim in reducing duration of severe neutropenia after chemotherapy for non-Hodgkin's lymphoma.
(Amer Soc Clinical Oncology, 2019)
[No Abstract Available]